Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Optimizing Formulation Strategies for Poorly Soluble Compounds: Insights into Bioavailability Enhancement and Accelerated Development

ET
60 Minutes

With 70% of small molecule drug candidates classified as poorly soluble (BCS Class II and IV), achieving adequate absorption in the gastrointestinal (GI) tract remains a critical challenge in drug development. This webinar delves into effective formulation strategies to overcome these solubility and bioavailability hurdles.

Join us as we explore the latest advancements in bioavailability enhancement technologies, including hot melt extrusion (HME) and spray dried dispersion (SDD), which are gaining momentum in the industry. We'll discuss the critical factors to consider when selecting the optimal formulation approach during the late discovery and pre-clinical phases, emphasizing that no single solution fits all scenarios.

The session will include:

  • A comprehensive review of current and emerging bioavailability enhancement technologies
  • Key considerations for leveraging HME and SDD to streamline development
  • Real-world case studies demonstrating how strategic formulation approaches can reduce development timelines by up to 50% toward IND filing

Speakers

Feng Zhang

Feng Zhang, Ph.D.

Associate Professor of Molecular Pharmaceutics and Drug Delivery
University of Texas at Austin

Having received from China Pharmaceutical University a B.S. in Pharmaceutical Science (1994), Feng Zhang graduated from Molecular Pharmaceutics and Drug Delivery department at University of Texas at Austin with a Ph.D. in Pharmaceutical Science (1999). He worked at PharmaForm (2000-2010) and Gilead Sciences (2011-2013), prior to joining the College of Pharmacy at the University of Texas at Austin (Jan 2014). Feng Zhang was promoted to Associate Professor with tenure in September 2020.

His team’s research interests include (1) formulation, processing, and characterization of melt-extruded long-acting implants, (2) investigation of process-induced transformation of API during twin-screw continuous granulation, and (3) simulation and modeling of melt extrusion for preparing amorphous solid dispersions to enhance bioavailability of BCS Class 2 and 4 drugs.

Hong Li

Hong Li, Ph.D.

VP of Formulation
BioDuro

Dr. Hong Li brings over 20 years of expertise to the pharmaceutical industry, specializing in new and generic drug formulation and process development. As the leader of a dynamic formulation development team, she guides projects from initial assessments to product launches, encompassing, packaging, labelling and product life cycle management. Dr. Hong Li is renowned for her comprehensive understanding of FDA, NMPA regulations, and adherence to ICH guidelines. Her strategic insight and commitment to innovation make her a distinguished figure in the ever-evolving landscape of pharma services.

Register here!

Already registered? Click here to login.
Date/Time:
ET
Duration:
60 Minutes